- Scienture posted a net loss of $41.5 million for 2025, swinging from net income of $9.1 million.
- Revenue more than tripled to $431,609.
- Gross margin widened 72.4 percentage points to 76.8%.
- Cash and cash equivalents climbed to about $6.7 million.
- Management pointed to momentum for Arbli, while targeting a commercial launch of REZENOPY in Q2 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300807PRIMZONEFULLFEED9680626) on March 30, 2026, and is solely responsible for the information contained therein.
Comments